Dr Reddy’s will manufacture and sell Eli Lilly’s COVID-19, Baricitinib, in India; 5th pharmacist to do so

Dr Reddy’s Laboratories have entered into a voluntary, non-exclusive, royalty-free license agreement with the US pharmaceutical company Eli Lilly and Company for the manufacture and sale of the drug, baricitinib. Baricitinib has received a ‘restricted emergency use authorization’ from the Ministry of Health’s central standard drug control organization for use in combination with remdesivir for the treatment of patients with suspected or confirmed COVID -19 which require supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO).

Deepak Sapra, CEO, API and Services, Dr Reddy’s Laboratories, said: “From the start, we were determined to explore all possible avenues against COVID-19. Our collaboration with Lilly will help us make another treatment option available to patients in India. Lilly has also licensed Cipla, Lupine, Natco and Sun Pharmaceutical to manufacture and sell the low cost versions of its new COVID-19, Baricitinib in India.

Dr Reddy’s has also linked up with the Russian Direct Investment Fund, the Russian sovereign wealth fund that funded Sputnik V and is responsible for marketing it abroad, for the manufacture and sale of the vaccine in India. Dr Reddy’s also managed the clinical trials of Sputnik V in India. The vaccine has received drug regulatory approval in India and the country will start receiving doses of Sputnik V from May.

According to Deepak Sapra, CEO of Dr Reddy Laboratories, six manufacturing units have been selected for the production of Sputnik V in India. Two of these units will start supplying vaccines by June-July, the other two by August, and the other two are expected to start supplying the vaccine in September or October.

He also collaborated with DRDO (Defense Research and Development Organization) to develop an anti-Covid drug, 2-deoxy-D-glucose (2-DG), which also received the approval of the Drugs Controller General. of India (DCGI). The drug was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a laboratory of the Defense Research and Development Organization (DRDO), in collaboration with Dr Reddy’s laboratories in Hyderabad.

INMAS-DRDO scientists had in April 2020, during the first wave of COVID-19, conducted laboratory experiments with the help of the Center for Cellular and Molecular Biology (CCMB), Hyderabad. Researchers have found that this molecule works effectively against the SARS-CoV-2 virus and prevents viral growth.

Dr Reddy’s stock rose from Rs 4.05 or 0.076 percent to Rs 5,300 on the National Stock Exchange on Wednesday. Meanwhile, India has reported 3,48421 new cases of COVID-19 and the highest 4,205 deaths in the past 24 hours, as data from the Ministry of Health shows.

Also Read: Cipla, Lupine, Sun Pharma To Make And Sell Low Cost Versions Of Lilly’s COVID-19 Drug

Also read: India Approves Roche Antibody Cocktail to Treat COVID-19; Cipla to distribute the drug

About Hector Hedgepeth

Check Also

Collaborate with academia for drug discovery targeting immune-mediated diseases

By George Vratsanos, MD, and Luke Devey, MD, Ph.D., Janssen Immunology There are many critical …

Leave a Reply

Your email address will not be published.